PCN99 THE COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF RITUXIMAB(HANLIKANG) FOR PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA IN CHINA
Nov 1, 2019, 00:00
10.1016/j.jval.2019.09.296
https://www.valueinhealthjournal.com/article/S1098-3015(19)32674-9/fulltext
Title :
PCN99 THE COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF RITUXIMAB(HANLIKANG) FOR PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA IN CHINA
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)32674-9&doi=10.1016/j.jval.2019.09.296
First page :
Section Title :
Open access? :
No
Section Order :
10240